FDA Approves Second Treatment for Ebola Virus

Article

The FDA approved ansuvimab-zykl (Ebanga; Ridgeback Biotherapeutics) for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children.

Officials with the FDA have approved ansuvimab-zykl (Ebanga; Ridgeback Biotherapeutics) for the treatment of Zaire ebolavirus (Ebolavirus) infection in adults and children, according to a press release.

Ansuvimab-zykl is the second treatment to receive FDA approval for the treatment of Ebola virus. A monoclonal antibody mixture composed of atoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb; Regeneron) was approved in October 2020.

Ansuvimab-zykl, a human monoclonal antibody, was evaluated in the PALM clinical trial amid the Ebola outbreak in the Democratic Republic of the Congo in 2018-2019.

In the multi-center, open-label, randomized controlled PALM study, 174 patients (120 adults and 54 pediatric patients) with confirmed Ebola virus infection received ansuvimab-zykl intravenously as a single 50 mg/kg infusion, and 168 participants (135 adults and 33 pediatric patients) received an investigational control. Of those patients who received ansuvimab-zykl, 35.1% died after 28 days, compared with 49.4% of the patients who received a control therapy.

The most commonly reported adverse effects (AEs) in the trial include fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills; however, these are also common symptoms of the Ebola virus infection, according to the FDA.

According to the FDA, patients who receive ansuvimab-zykl should avoid the concurrent administration of a live virus vaccine against Ebola virus, as there is a potential for the drug to inhibit replication of a live vaccine virus and possibly reduce the efficacy of the vaccine.

Reference:

  1. FDA Approves Treatment for Ebola Virus. News release. FDA; December 21, 2020. Accessed December 22, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-treatment-ebola-virus

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.